Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Discusses Therapeutic Benefits of Cannabis During Annual International League Against Epilepsy Meeting

Renowned Mexican Neurologist Presents on Effects of Real Scientific Hemp Oil-X™ (RSHO-X™) in Treating Children with Severe Epilepsy

SAN DIEGO, July 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico participated in the LX Annual Meeting and National Congress of the Mexican Chapter of the International League Against Epilepsy, which took place in Tijuana, Mexico from July 26th to 29th.

HempMeds® Mexico provided information about cannabinoid products for the treatment of neurodegenerative conditions, such as epilepsy, as well as the results obtained by Mexican doctors using the first cannabis based treatment approved in Mexico that is the Company’s Real Scientific Hemp Oil-X™ (RSHO-X™).

Mexican pediatric neurologist Dr. Saul Garza Morales presented information from a study involving 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period, with zero reported side effects.

“This was an incredible opportunity to meet with other doctors and discuss the latest research in the cannabinoid space,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It was wonderful to see presentations made regarding the Endogenous Cannabinoid System and view some of the emerging science behind cannabinoids and effects upon the neurological systems.”

HempMeds® Mexico is committed to educating the medical community about the therapeutic benefits of cannabinoids and to provide accurate information about its impact in the treatment of neurodegenerative diseases.

About HempMeds® Mexico  
HempMeds®Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexicoplans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at:

About Medical Marijuana, Inc.    
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

Public Relations Contact: 
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
[email protected]